Personalized busulfan dosing for nonstandard transplant candidates
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a personalized way to adjust busulfan dosing (a chemotherapy drug) during an allogeneic stem cell transplant conditioning regimen. It aims to help adults who cannot receive the usual “high-intensity” conditioning due to age or other health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 65 or younger
- You have one of these: acute leukemia, myelodysplastic syndrome, or myeloproliferative neoplasm that can be treated with an allogeneic transplant
- Your disease is responding or stable (complete, partial, or stable remission)
- You have a donor match option: identical family donor, half-matched (haplo-identical), or unrelated donor with overall HLA compatibility about 8/10 to 10/10
- You are not eligible for standard high-intensity conditioning (often due to age 45+ or other health conditions)
- You can agree to follow the trial plan and attend follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
This study tests a different way to calculate how much busulfan (a medicine used before a stem cell transplant) to give to children. By using body surface area (a measure of body size), they hope to find the right dose for each child.
This trial tests a transplant using stem cells from an unrelated donor who is not a perfect match for your tissue type. It may be an option for people with blood cancers who can't find a fully matched related donor and need a transplant quickly.
This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.